DEVELOP is a multicenter, prospective, observational registry of the long-term safety and clinical status of 6070 pediatric patients with inflammatory bowel disease (IBD; Crohn’s disease [CD]: 4122, ulcerative colitis [UC]: 1643, and IBD-unclassified[IBD-U]: 305; median age at enrollment 13.0 years) treated with originator infliximab (REM) and/or other medical therapies for IBD as part of routine clinical care. DEVELOP has sites in the United States, Canada and the EU and enrolled patients from 2007 to 2017.